PBMs: PBM TARGETED IN NEW WHISTLEBLOWER SUIT

Why This Topic Matters

The piece highlights how fraud enforcement is expanding beyond manufacturers to include pharmacy benefit managers and related entities, making it relevant for organizations monitoring compliance risk, whistleblower exposure, and government investigation trends.

Article Sections

1. Enforcement trends and drug-industry scrutiny

   Introduces broader fraud-enforcement activity affecting drug manufacturers, physicians, and pharmacy-related business partners. It sets the context for the whistleblower matter discussed later in the article.

2. DOJ intervention in whistleblower suits against a PBM

   Summarizes the reported government intervention in litigation involving a pharmacy benefit manager and describes the general categories of alleged misconduct raised in the complaints. The section also notes the parties, procedural posture, and the company’s response.

3. Lesson learned

   Provides a brief takeaway about the direction of fraud enforcement and the types of health care entities that may face increased scrutiny.